Clinical Trials Logo
  1. Home
  2. Antidepressive Agents
  3. NCT03195231

Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease

Antidepressive Agents Clinical Trial

Official title:
Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.

Clinical Trial Summary

Depression is one of the most important nonmotor features of idiopathic PD（Parkinson's disease ）which may not just interfere with the motor symptoms of PD but can also cause immense personal suffering as well as decreased quality of life with increased disability and caregiver burden. However,there is little hard evidence to guide clinical treatment. Although some newer dopamine agonists also have antidepressive effect, the use of tricyclic or nontricyclic antidepressants is frequently required.However, the side-effects of these agents may also worsen some preexisting nonmotor problems in PD. Wuling powder is a Chinese medicine which is made by cultivating Xylariasp mycelium using submerged fermentation technology. Xylariasp is the fungus sclerotia which grow in termite nests. Wuling powder is mainly used to soothe nerves and anti-insomnia in clinical. The antidepressant effect of Wuling powder has been confirmed in clinical, but not in the patients of Parkinson`s disease. Therefore, the investigators design a randomized, double-blind, placebo-controlled study to evaluate the antidepressant effect of Wuling powder in PD patients and its underlying mechanism.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03195231
Study type Interventional
Source Beijing Hospital
Contact Xin Wang
Phone +8613661174001
Email wangxinannie@126.com
Status Not yet recruiting
Phase Phase 4
Start date June 25, 2017
Completion date January 15, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT02263872 - Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Phase 4
Completed NCT04985305 - Optimization of Deprescribing Antidepressants in Nursing Home Residents With Dementia N/A
Recruiting NCT04161209 - Citalopram and Stress Reactivity N/A
Recruiting NCT04169230 - Citalopram and Self Emotional Processing N/A
Completed NCT05128812 - Study of the Effects of Plx on Bioparametric Measurements. N/A
Recruiting NCT05842928 - Patient-centred Deprescribing of Psychotropic, Sedative and Anticholinergic Medication in Elderly Patients With Polypharmacy N/A
Recruiting NCT01204086 - Pharmacogenomics Studies of Antidepressants Phase 4
Recruiting NCT05616559 - Precision Medicine in the Depression Treatment
Completed NCT03572790 - Effects of Seven Day Prucalopride Administration in Healthy Volunteers N/A
Active, not recruiting NCT05356078 - Association Between Prescription of Antidepressants and Delirium in the Elderly : Analysis From the World Health Organization Global Database
Completed NCT03863366 - Effects of Acute Prucalopride Administration in Healthy Volunteers N/A
Completed NCT04806230 - Serum Concentrations of Antidepressant Drugs in Pregnant Women - a Naturalistic Study